D Tomek

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications

Alessandra Ferrario, Diāna Arāja, Tomasz Bochenek et al. · PharmacoEconomics · 2017 · 121 citations · Full text

Public Affairs, Pharmaceutical Policy, Health Technology Assessment +8

Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries

Brian Godman, Holly McCabe, Trudy Leong et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2020 · 92 citations · Full text

Pharmacy, Pharmaceutical Policy, Pharmacoeconomics +17

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

Rickard E. Malmström, Brian Godman, Eduard Diogène et al. · Frontiers in Pharmacology · 2013 · 91 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Brian Godman, Andrew Hill, Steven Simoens et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2021 · 73 citations · Full text

Pharmacy, Oncology, Pharmaceutical Policy +17

Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA

Patricia Vella Bonanno, Anna Bucsics, Steven Simoens et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2019 · 46 citations · Full text

Social Sciences, Health Law, Health Policy +13